{"drugs":["Camptosar","Irinotecan Hydrochloride","Novaplus Irinotecan Hydrochloride"],"mono":[{"id":"923686-s-0","title":"Generic Names","mono":"Irinotecan Hydrochloride"},{"id":"923686-s-1","title":"Dosing and Indications","sub":[{"id":"923686-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Extensive stage small cell lung cancer, First-line treatment, in combination with cisplatin:<\/b> 60 mg\/m(2) IV on days 1, 8, and 15 PLUS cisplatin 60 mg\/m(2) IV on day 1, repeat every 4 weeks for 4 cycles  OR 65 mg\/m(2) IV on days 1 and 8 PLUS cisplatin 30 mg\/m(2) IV on days 1 and 8, repeat every 3 weeks for at least 4 cycles  has been used in randomized phase 3 clinical trials.<\/li><li><b>Gastric cancer:<\/b> (Second-line therapy): 150 mg\/m(2) IV on days 1 and 15 every 4 weeks (study dose)<\/li><li><b>Metastatic colorectal cancer, First-line therapy, in combination with 5-fluorouracil and leucovorin:<\/b> (once weekly regimen with bolus 5-fluorouracil\/leucovorin) initial, 125 mg\/m(2) IV over 90 minutes in combination with leucovorin 20 mg\/m(2) IV bolus and 5-fluorouracil 500 mg\/m(2) IV bolus given on days 1, 8, 15, and 22; irinotecan should be administered first followed by leucovorin and then 5-fluorouracil; consider reducing the initial dose by at least one dose level in patients with the homozygous UGT1A1*28 al&le;; premedicate with antiemetics at least 30 minutes prior to treatment and consider prophylactic atropine 0.25 to 1 mg IV or subQ to prevent diarrhea<\/li><li><b>Metastatic colorectal cancer, First-line therapy, in combination with 5-fluorouracil and leucovorin:<\/b> (once weekly regimen with bolus 5-fluorouracil\/leucovorin) subsequent cycles, do not administer until the granulocyte count is 1500 cells\/mm(3) or greater, the platelet count is 100,000 cells\/mm(3) or greater, any toxicity is resolved to National Cancer Institute grade 1 or less, and treatment-related diarrhea is resolved (with no antidiarrhea medication for at least the proceeding 24 hours); dose may be decreased depending on individual tolerability; administer dose IV over 90 minutes on days 1, 8, 15, and 22 (with 5-fluorouracil\/leucovorin); repeat cycles every 6 weeks until loss of clinical benefit or the development of intolerable toxicity; consider discontinuing therapy if a toxicity leads to a treatment delay exceeding 2 weeks; premedicate with antiemetics at least 30 minutes prior to treatment and consider prophylactic atropine 0.25 to 1 mg IV or subQ to prevent diarrhea in patients who experience cholinergic symptoms<\/li><li><b>Metastatic colorectal cancer, First-line therapy, in combination with 5-fluorouracil and leucovorin:<\/b> (once every 2 week regimen with infusional 5-fluorouracil\/leucovorin) initial, 180 mg\/m(2) IV over 90 minutes on days 1, 15, and 29 in combination with leucovorin 200 mg\/m(2) IV over 2 hours on days 1, 2, 15, 16, 29, and 30, and 5-fluorouracil 400 mg\/m(2) IV bolus followed by 600 mg\/m(2) IV over 22 hours given on days 1, 2, 15, 16, 29, and 30; irinotecan should be administered first on days 1, 15 and 29 and leucovorin should always be administered prior to 5-fluorouracil; consider reducing the initial dose by at least one dose level in patients with the homozygous UGT1A1*28 al&le;; premedicate with antiemetics at least 30 minutes prior to treatment and consider prophylactic atropine 0.25 to 1 mg IV or subQ to prevent diarrhea<\/li><li><b>Metastatic colorectal cancer, First-line therapy, in combination with 5-fluorouracil and leucovorin:<\/b> (once every 2 week regimen with infusional 5-fluorouracil\/leucovorin) subsequent cycles, do not administer until the granulocyte count is 1500 cells\/mm(3) or greater, the platelet count is 100,000 cells\/mm(3) or greater, any toxicity is resolved to National Cancer Institute grade 1 or less, and treatment-related diarrhea is resolved (with no antidiarrhea medication for at least the proceeding 24 hours); dose may be decreased depending on individual tolerability; administer dose IV over 90 minutes on days 1, 15, and 29 (with 5-fluorouracil\/leucovorin); repeat cycles every 6 weeks until loss of clinical benefit or the development of intolerable toxicity; consider discontinuing therapy if a toxicity leads to a treatment delay exceeding 2 weeks premedicate with antiemetics at least 30 minutes prior to treatment and consider prophylactic atropine 0.25 to 1 mg IV or subQ to prevent diarrhea in patients who experience cholinergic symptoms<\/li><li><b>Metastatic colorectal cancer, In patients whose disease has recurred\/progressed after initial 5-fluorouracil-based therapy:<\/b> (weekly regimen) initial, 125 mg\/m(2) IV over 90 minutes on days 1, 8, 15, and 22 followed by a 2-week rest; consider starting patients with prior pelvic\/abdominal radiotherapy, a performance status of 2, increased bilirubin levels, or an age of 65 years or older at a reduced dose of 100 mg\/m(2); consider reducing the initial dose by at least one dose level in patients with the homozygous UGT1A1*28 al&le; (dose level -1, 100 mg\/m(2); dose level -2, 75 mg\/m(2)); premedicate with antiemetics (eg, dexamethasone 10 mg plus a 5-hydroxytryptamine-3 receptor blocker) at least 30 minutes prior to treatment and consider prophylactic atropine 0.25 to 1 mg IV or subQ to prevent diarrhea<\/li><li><b>Metastatic colorectal cancer, In patients whose disease has recurred\/progressed after initial 5-fluorouracil-based therapy:<\/b> (weekly regimen) subsequent cycles, do not administer until the granulocyte count is 1500 cells\/mm(3) or greater, the platelet count is 100,000 cells\/mm(3) or greater, any toxicity is resolved to National Cancer Institute grade 1 or less, and treatment-related diarrhea is resolved; dose may be increased to 150 mg\/m(2) IV (if no toxicity) or decreased in 25 to 50 mg decrements to a minimum dose of 50 mg\/m(2) depending on individual tolerability; administer dose IV over 90 minutes on days 1, 8, 15, and 22 followed by a 2-week rest; repeat cycles until loss of clinical benefit or the development of intolerable toxicity; consider discontinuing therapy if a toxicity leads to a treatment delay exceeding 2 week; premedicate with antiemetics (eg, dexamethasone 10 mg plus a 5-hydroxytryptamine-3 receptor blocker) at least 30 minutes prior to treatment and consider prophylactic atropine 0.25 to 1 mg IV or subQ to prevent diarrhea in patients who experience cholinergic symptoms<\/li><li><b>Metastatic colorectal cancer, In patients whose disease has recurred\/progressed after initial 5-fluorouracil-based therapy:<\/b> (once every 3 week regimen) initial, 350 mg\/m(2) IV over 90 minutes on day 1, repeat every 3 week; initial dose for patients 70 years or older is 300 mg\/m(2); the maximum dose was 700 mg in 2 clinical trials; consider starting patients with prior pelvic\/abdominal radiotherapy, a performance status of 2, increased bilirubin levels, or an age of 65 years or older at a reduced dose of 300 mg\/m(2); consider reducing the initial dose by at least one dose level in patients with the homozygous UGT1A1*28 al&le; (dose level -1, 300 mg\/m(2); dose level -2, 250 mg\/m(2)); premedicate with antiemetics at least 30 minutes prior to treatment and consider prophylactic atropine 0.25 to 1 mg IV or subQ to prevent diarrhea<\/li><li><b>Metastatic colorectal cancer, In patients whose disease has recurred\/progressed after initial 5-fluorouracil-based therapy:<\/b> (once every 3 week regimen) subsequent cycles, do not administer until the granulocyte count is 1500 cells\/mm(3) or greater, the platelet count is 100,000 cells\/mm(3) or greater, any toxicity is resolved to National Cancer Institute grade 1 or less, and treatment-related diarrhea is resolved; dose may be decreased in 50 mg decrements to a minimum dose of 200 mg\/m(2) depending on individual tolerability; administer dose IV over 90 minutes on day 1, repeat every 3 weeks; repeat cycles until loss of clinical benefit or the development of intolerable toxicity; consider discontinuing therapy if a toxicity leads to a treatment delay exceeding 2 weeks premedicate with antiemetics at least 30 minutes prior to treatment and consider prophylactic atropine 0.25 to 1 mg IV or subQ to prevent diarrhea in patients who experience cholinergic symptoms<\/li><li><b>Non-small cell lung cancer:<\/b> 60 mg\/m(2) IV on days 1, 8, and 15 has been used in combination with cisplatin 80 mg\/m(2) IV on day 1; courses were repeated every 4 weeks<\/li><li><b>Ovarian cancer, Platinum-refractory or platinum-resistant:<\/b> optimal dosing and timing not defined; clinical trials have used doses of 200 mg\/m(2) IV with docetaxel 60 mg\/m(2) every 3 weeks; irinotecan 120 mg\/m(2) IV days 1 and 15 with mitomycin C 7 mg\/m(2) IV days 1 and 15, every 4 weeks; irinotecan 250 to 300 mg\/m(2) IV as monotherapy every 3 weeks<\/li><\/ul>"},{"id":"923686-s-1-5","title":"Pediatric Dosing","mono":"efficacy not established in pediatric patients "},{"id":"923686-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>diarrhea (grade 1 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, maintain dose; at the start of subsequent cycles of therapy; maintain the same dose as in the previous cycle<\/li><li><b>diarrhea (grade 1 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil and leucovorin, delay therapy until resolved to baseline, then give same doses; at the start of subsequent cycles of therapy, maintain the same doses as in the previous cycle<\/li><li><b>diarrhea (grade 2 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, reduce dose by 25 mg\/m(2); at the start of subsequent cycles of therapy, maintain the same dose as in the previous cycle<\/li><li><b>diarrhea (grade 2 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (LV), omit therapy until resolved to baseline, then reduce by one dose level (weekly regimen: dose level -1, irinotecan 100 mg\/m(2), LV 20 mg, and 5-FU 400 mg; dose level -2, irinotecan 75 mg\/m(2), LV 20 mg\/m(2), and 5-FU 300 mg\/m(2); once every 2 week regimen: dose level -1, irinotecan 150 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 320 mg\/m(2), 5-FU 22-hr infusion 480 mg\/m(2); dose level -2, irinotecan 120 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 240 mg\/m(2), 5-FU 22-hr infusion 360 mg\/m(2)); at the start of subsequent cycles of therapy, maintain the same dose as in the previous cycle<\/li><li><b>diarrhea (grade 3 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, omit dose until resolved to grade 2 or less, then reduce dose by 25 mg\/m(2); at the start of subsequent cycles of therapy, reduce dose (relative to the starting dose in the previous cycle) by 25 mg\/m(2) for the once weekly regimen and by 50 mg\/m(2) for the every 3 week regimen<\/li><li><b>diarrhea (grade 3 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (LV), omit therapy until resolved to baseline, then reduce therapy by one dose level (weekly regimen: dose level -1, irinotecan 100 mg\/m(2), LV 20 mg, and 5-FU 400 mg; dose level -2, irinotecan 75 mg\/m(2), LV 20 mg\/m(2), and 5-FU 300 mg\/m(2); once every 2 week regimen: dose level -1, irinotecan 150 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 320 mg\/m(2), 5-FU 22-hr infusion 480 mg\/m(2); dose level -2, irinotecan 120 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 240 mg\/m(2), 5-FU 22-hr infusion 360 mg\/m(2)); at the start of subsequent cycles of therapy, reduce (relative to starting doses in the previous cycle) by one dose level<\/li><li><b>diarrhea (grade 4 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, omit dose until resolved to grade 2 or less, then reduce dose by 50 mg\/m(2); at the start of subsequent cycles of therapy, reduce dose (relative to the starting dose in the previous cycle) by 50 mg\/m(2) for the once weekly regimen and the every 3 week regimen<\/li><li><b>diarrhea (grade 4 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (LV), omit therapy until resolved to baseline, then reduce therapy by 2 dose levels (weekly regimen: dose level -2, irinotecan 75 mg\/m(2), LV 20 mg\/m(2), and 5-FU 300 mg\/m(2); once every 2 week regimen: dose level -2, irinotecan 120 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 240 mg\/m(2), 5-FU 22-hr infusion 360 mg\/m(2)); at the start of subsequent cycles of therapy, reduce (relative to starting doses in the previous cycle) by 2 dose levels; may further decrease doses by approximately 20% if toxicity persists after reducing the regimen to dose level -2<\/li><li><b>geriatric (aged 65 years or older):<\/b> recurrent or progressive metastatic colorectal cancer, consider reducing the initial single-agent dose to 100 mg\/m(2) for the once weekly regimen and 300 mg\/m(2) for the every 3 week regimen<\/li><li><b>geriatric (aged 70 years or older):<\/b> recurrent or progressive metastatic colorectal cancer, reduce the initial single-agent once every 3 week dose to 300 mg\/m(2)<\/li><li><b>hematologic toxicity including neutropenia, leukopenia, thrombocytopenia, and anemia (grade 1 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, maintain dose; at the start of subsequent cycles of therapy, maintain the same dose as in the previous cycle<\/li><li><b>hematologic toxicity including neutropenia, leukopenia, and thrombocytopenia (grade 1 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil and leucovorin, maintain therapy doses; at the start of subsequent cycles of therapy, maintain same doses as in the previous cycle<\/li><li><b>hematologic toxicity including neutropenia, leukopenia, thrombocytopenia, and anemia (grade 2 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, reduce dose by 25 mg\/m(2); at the start of subsequent cycles of therapy, maintain the same dose as in the previous cycle<\/li><li><b>hematologic toxicity including neutropenia, leukopenia, and thrombocytopenia (grade 2 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (LV), reduce therapy by one dose level (weekly regimen: dose level -1, irinotecan 100 mg\/m(2), LV 20 mg, and 5-FU 400 mg; dose level -2, irinotecan 75 mg\/m(2), LV 20 mg\/m(2), and 5-FU 300 mg\/m(2); once every 2 week regimen: dose level -1, irinotecan 150 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 320 mg\/m(2), 5-FU 22-hr infusion 480 mg\/m(2); dose level -2, irinotecan 120 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 240 mg\/m(2), 5-FU 22-hr infusion 360 mg\/m(2)); at the start of subsequent cycles of therapy, maintain same doses as in the previous cycle<\/li><li><b>hematologic toxicity including neutropenia, leukopenia, thrombocytopenia, and anemia (grade 3 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, omit dose until resolved to grade 2 or less, then reduce dose by 25 mg\/m(2); at the start of subsequent cycles of therapy, reduce dose (relative to the starting dose in the previous cycle) by 25 mg\/m(2) for the once weekly regimen and by 50 mg\/m(2) for the every 3 week regimen<\/li><li><b>hematologic toxicity including neutropenia, leukopenia, and thrombocytopenia (grade 3 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (LV), omit therapy until resolved to grade 2 or less, then reduce therapy by one dose level (weekly regimen: dose level -1, irinotecan 100 mg\/m(2), LV 20 mg, and 5-FU 400 mg; dose level -2, irinotecan 75 mg\/m(2), LV 20 mg\/m(2), and 5-FU 300 mg\/m(2); once every 2 week regimen: dose level -1, irinotecan 150 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 320 mg\/m(2), 5-FU 22-hr infusion 480 mg\/m(2); dose level -2, irinotecan 120 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 240 mg\/m(2), 5-FU 22-hr infusion 360 mg\/m(2)); at the start of subsequent cycles of therapy, reduce (relative to starting doses in the previous cycle) by one dose level<\/li><li><b>hematologic toxicity including neutropenia, leukopenia, thrombocytopenia, and anemia (grade 4 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, omit dose until resolved to grade 2 or less, then reduce dose by 50 mg\/m(2); at the start of subsequent cycles of therapy, reduce dose (relative to the starting dose in the previous cycle) by 50 mg\/m(2) for the once weekly regimen and the every 3 week regimen<\/li><li><b>hematologic toxicity including neutropenia, leukopenia, and thrombocytopenia (grade 4 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (LV), omit therapy until resolved to grade 2 or less, then reduce therapy by 2 dose levels (weekly regimen: dose level -2, irinotecan 75 mg\/m(2), LV 20 mg\/m(2), and 5-FU 300 mg\/m(2); once every 2 week regimen: dose level -2, irinotecan 120 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 240 mg\/m(2), 5-FU 22-hr infusion 360 mg\/m(2)); at the start of subsequent cycles of therapy, reduce (relative to starting doses in the previous cycle) by 2 dose levels; may further decrease doses by approximately 20% if toxicity persists after reducing the regimen to dose level -2<\/li><li><b>hepatic impairment (increased bilirubin level):<\/b> recurrent or progressive metastatic colorectal cancer, consider reducing the initial dose to 100 mg\/m(2) for the once weekly regimen and 300 mg\/m(2) for the every 3 week regimen<\/li><li><b>nonhematologic toxicity excluding alopecia, anorexia, and asthenia (grade 1 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, maintain dose; at the start of subsequent cycles of therapy, maintain the same dose as in the previous cycle<\/li><li><b>nonhematologic toxicity excluding diarrhea, alopecia, anorexia, and asthenia (grade 1 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil and leucovorin, maintain therapy doses; at the start of subsequent cycles of therapy, maintain the same doses as in the previous cycle<\/li><li><b>nonhematologic toxicity excluding diarrhea, alopecia, anorexia, and asthenia (grade 2 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, reduce dose by 25 mg\/m(2); at the start of subsequent cycles of therapy, reduce dose (relative to the starting dose in the previous cycle) by 25 mg\/m(2) for the once weekly regimen and by 50 mg\/m(2) for the every 3 week regimen<\/li><li><b>nonhematologic toxicity excluding diarrhea, alopecia, anorexia, and asthenia (grade 2 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (LV), omit therapy until resolved grade 1 or less, then reduce by one dose level (weekly regimen: dose level -1, irinotecan 100 mg\/m(2), LV 20 mg, and 5-FU 400 mg; dose level -2, irinotecan 75 mg\/m(2), LV 20 mg\/m(2), and 5-FU 300 mg\/m(2); once every 2 week regimen: dose level -1, irinotecan 150 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 320 mg\/m(2), 5-FU 22-hr infusion 480 mg\/m(2); dose level -2, irinotecan 120 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 240 mg\/m(2), 5-FU 22-hr infusion 360 mg\/m(2)); at the start of subsequent cycles of therapy, maintain the same doses as in the previous cycle; for mucositis\/stomatitis, only decrease 5-FU<\/li><li><b>nonhematologic toxicity excluding alopecia, anorexia, and asthenia (grade 3 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, omit dose until resolved to grade 2 or less, then reduce dose by 25 mg\/m(2); at the start of subsequent cycles of therapy, reduce dose (relative to the starting dose in the previous cycle) by 25 mg\/m(2) for the once weekly regimen and by 50 mg\/m(2) for the every 3 week regimen<\/li><li><b>nonhematologic toxicity excluding diarrhea, alopecia, anorexia, and asthenia (grade 3 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (LV), omit therapy until resolved to grade 2 or less, then reduce therapy by one dose level (weekly regimen: dose level -1, irinotecan 100 mg\/m(2), LV 20 mg, and 5-FU 400 mg; dose level -2, irinotecan 75 mg\/m(2), LV 20 mg\/m(2), and 5-FU 300 mg\/m(2); once every 2 week regimen: dose level -1, irinotecan 150 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 320 mg\/m(2), 5-FU 22-hr infusion 480 mg\/m(2); dose level -2, irinotecan 120 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 240 mg\/m(2), 5-FU 22-hr infusion 360 mg\/m(2)); at the start of subsequent cycles of therapy, reduce (relative to starting doses in the previous cycle) by one dose level; for mucositis\/stomatitis, only decrease 5-FU<\/li><li><b>nonhematologic toxicity excluding alopecia, anorexia, and asthenia (grade 4 during a cycle of therapy):<\/b> recurrent or progressive metastatic colorectal cancer, omit dose until resolved to grade 2 or less, then reduce dose by 50 mg\/m(2); at the start of subsequent cycles of therapy, reduce dose (relative to the starting dose in the previous cycle) by 50 mg\/m(2) for the once weekly regimen and the every 3 week regimen<\/li><li><b>nonhematologic toxicity excluding diarrhea, alopecia, anorexia, and asthenia (grade 4 during a cycle of therapy):<\/b> first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (LV), omit therapy until resolved to grade 2 or less, then reduce therapy by 2 dose levels (weekly regimen: dose level -2, irinotecan 75 mg\/m(2), LV 20 mg\/m(2), and 5-FU 300 mg\/m(2); once every 2 week regimen: dose level -2, irinotecan 120 mg\/m(2), LV 200 mg\/m(2), 5-FU bolus 240 mg\/m(2), 5-FU 22-hr infusion 360 mg\/m(2)); at the start of subsequent cycles of therapy, reduce (relative to starting doses in the previous cycle) by 2 dose levels; may further decrease doses by approximately 20% if toxicity persists after reducing the regimen to dose level -2; for mucositis\/stomatitis, only decrease 5-FU<\/li><li><b>dialysis:<\/b> use not recommended<\/li><\/ul>"},{"id":"923686-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Metastatic colorectal cancer, First-line therapy, in combination with 5-fluorouracil and leucovorin<\/li><li>Metastatic colorectal cancer, In patients whose disease has recurred\/progressed after initial 5-fluorouracil-based therapy<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Acute lymphoid leukemia<\/li><li>Acute myeloid leukemia<\/li><li>Carcinoma of cervix<\/li><li>Carcinoma of esophagus<\/li><li>Colorectal cancer<\/li><li>Extensive stage small cell lung cancer, First-line treatment, in combination with carboplatin<\/li><li>Extensive stage small cell lung cancer, First-line treatment, in combination with cisplatin<\/li><li>Gastric cancer<\/li><li>Malignant glioma of brain, Recurrent or progressive disease<\/li><li>Metastatic breast cancer, Refractory<\/li><li>Non-Hodgkin's lymphoma<\/li><li>Non-small cell lung cancer<\/li><li>Ovarian cancer, Platinum-refractory or platinum-resistant<\/li><\/ul>"}]},{"id":"923686-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>Irinotecan can induce both early and late forms of diarrhea. Early diarrhea may be accompanied by cholinergic symptoms, which may be prevented or improved with atropine. Late diarrhea can be life threatening and should be treated immediately with loperamide. Initiate antibiotic therapy if ileus, fever, or severe neutropenia develop. Administration of irinotecan should be interrupted and subsequent doses reduced if severe diarrhea occurs. Severe myelosuppression may occur with irinotecan administration.<br\/>"},{"id":"923686-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923686-s-3-9","title":"Contraindications","mono":"Hypersensitivity to irinotecan or any component of the product <br\/>"},{"id":"923686-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Early or late diarrhea may occur; late diarrhea may be life-threatening due to possible dehydration, electrolyte imbalance, and sepsis; monitor and dose reduction or interruption of therapy may be necessary<\/li><li>-- Severe and life-threatening myelosuppression may occur; dose reduction or interruption required<\/li><li>Immunologic:<\/li><li>-- Severe anaphylactic and anaphylactoid reactions have been reported; discontinue if reaction occurs<\/li><li>Hepatic:<\/li><li>-- Use with caution in patients with hepatic impairment<\/li><li>-- Elevated serum bilirubin levels (greater than 1 mg\/dL); increased risk for first cycle, grade 3 or 4 neutropenia; consider dose reduction<\/li><li>-- Gilbert's syndrome (deficient glucuronidation of bilirubin); increased risk of myelosuppression<\/li><li>Renal:<\/li><li>-- Renal impairment and acute renal failure have been reported, especially in patients with severe vomiting and\/or diarrhea that led to volume depletion<\/li><li>-- Use with caution in patients with renal impairment<\/li><li>-- Patients on dialysis; use not recommended<\/li><li>Reproductive:<\/li><li>-- Fetal harm may occur; pregnancy should be avoided<\/li><li>Respiratory:<\/li><li>-- Interstitial pulmonary disease (IPD)-like events, including fatalities, have been reported; increased risk in patients with pre-existing lung disease or receiving concomitant radiation therapy, colony stimulating factors, or other pneumotoxic drugs; monitor at risk patients closely for respiratory symptoms before and during treatment; interrupt treatment if suspected and discontinue if diagnosed<\/li><li>Other:<\/li><li>-- Homozygous for UGT1A1*28 al&le; at increased risk of neutropenia; consider initial dose reduction and subsequent dose adjustments<\/li><li>-- Elderly patients (greater than 65 years of age) at increased risk of early or late diarrhea; monitoring recommended and dosage adjustment recommended for those 70 years or older<\/li><li>--Baseline performance status associated with higher incidence of hospitalization, neutropenic fever, thromboembolism, first-cycle discontinuation, and early death compared with patients with baseline performance status of 0 or 1; consider dose reduction<\/li><li>Concomitant Use:<\/li><li>-- Avoid diuretics or laxatives in patients with diarrhea<\/li><li>-- Concurrent irradiation not recommended<\/li><li>-- Concomitant use with 5-fluorouracil\/leucovorin regimen administered for 4 to 5 consecutive days every 4 weeks not recommended; may increase risk for toxicity including fatal toxicity<\/li><li>-- Avoid strong CYP3A4 inducers (eg, phenytoin, phenobarbital, carbamazepine, St. John's wort, rifampin, rifabutin) unless no therapeutic alteratives; at least 2 week prior to irinotecan initiation consider substituting with non-enzyme inducing therapy<\/li><li>-- Avoid strong CYP3A4 or UGT1A1 inhibitors (eg, ketoconazole, clarithromycin, indinavir, nefazodone, atazanavir, gemfibrozil) unless no therapeutic alternatives; discontinue strong CYP3A4 inhibitors 1 or more weeks prior to initiating irinotecan<\/li><\/ul>"},{"id":"923686-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Irinotecan: D (FDA)<\/li><li>Irinotecan: D (AUS)<\/li><\/ul>"},{"id":"923686-s-3-12","title":"Breast Feeding","mono":"Irinotecan: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"923686-s-4","title":"Drug Interactions","sub":[{"id":"923686-s-4-13","title":"Contraindicated","mono":"<ul><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (probable)<\/li><li>Nelfinavir (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rotavirus Vaccine, Live (established)<\/li><li>Saquinavir (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><\/ul>"},{"id":"923686-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Aprepitant (theoretical)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Carbamazepine (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Gemfibrozil (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Lopinavir (probable)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mitotane (theoretical)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Nefazodone (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Primidone (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Simeprevir (theoretical)<\/li><li>Smallpox Vaccine (established)<\/li><li>St John's Wort (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Teriflunomide (probable)<\/li><li>Typhoid Vaccine (established)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Voriconazole (theoretical)<\/li><li>Yellow Fever Vaccine (established)<\/li><\/ul>"},{"id":"923686-s-4-15","title":"Moderate","mono":"<ul>Citalopram (probable)<\/ul>"}]},{"id":"923686-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Alopecia (43.1% to 60%)<\/li><li><b>Endocrine metabolic:<\/b>Weight decreased (30%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (all grade, 17.2% to 67.7%; grade 3 and 4, 2.1% to 14%), Constipation (all grade, 30% to 43.9%; grade 3 and 4, 0.4% to 10%), Diarrhea, All grade (early-onset, 43% to 51%; late-onset, 72.4% to 88%), Loss of appetite (all grade, 34.2% to 55%; grade 3 and 4, 2.1% to 7.2%), Nausea (all grade, 66.9% to 86%; grade 3 and 4, 2.1% to 17%), Vomiting (all grade, 44.8% to 67%; grade 3 and 4, 3.5% to 14%)<\/li><li><b>Hematologic:<\/b>Anemia, All grade (60% to 97.2%), Drug-induced eosinophilia, Leukopenia, All grade (63% to 96.9%), Neutropenia, All grade (54% to 96.9%), Thrombocytopenia, All grade (32.6% to 96%)<\/li><li><b>Hepatic:<\/b>Increased bilirubin level (19.1% to 87.6%)<\/li><li><b>Neurologic:<\/b>Asthenia (all grade, 57.9% to 76%; grade 3 and 4, 9% to 19.5%), Dizziness (15% to 23.1%)<\/li><li><b>Respiratory:<\/b>Cough (17% to 26.7%), Dyspnea (9.7% to 27.6%)<\/li><li><b>Other:<\/b>Fever (42.2% to 45%), Infectious disease (13.9% to 35.9%), Pain (all grade, 22.9% to 64.1%; grade 3 and 4, 2% to 19%), Poisoning by parasympathomimetic drug (28.3%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Disorder of cardiovascular system<\/li><li><b>Gastrointestinal:<\/b>Diarrhea, Grade 3 and 4 (4.9% to 31%), Gastrointestinal perforation<\/li><li><b>Hematologic:<\/b>Anemia, Grade 3 and 4 (2.1% to 8.4%), Febrile neutropenia (adults, 2% to 7.1%; pediatrics, 8.8%), Hemorrhage (1% to 5%), Infectious disease, Neutropenic (1% to 2.2%), Leukopenia, Grade 3 and 4 (17.4% to 37.8%), Neutropenia, Grade 3 or 4 (adults, 26% to 53.8%; pediatrics, 31.8%), Thrombocytopenia, Grade 3 and 4 (up to 4%), Thromboembolic disorder (5.4% to 11.7%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Respiratory:<\/b>Interstitial lung disease<\/li><\/ul>"},{"id":"923686-s-6","title":"Drug Name Info","sub":{"0":{"id":"923686-s-6-17","title":"US Trade Names","mono":"<ul><li>Camptosar<\/li><li>Novaplus Irinotecan Hydrochloride<\/li><\/ul>"},"2":{"id":"923686-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Topoisomerase I Inhibitor<\/li><\/ul>"},"3":{"id":"923686-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923686-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"923686-s-7","title":"Mechanism Of Action","mono":"Irinotecan hydrochloride, a camptothecin derivative of topoisomerase 1 inhibitor class, prevents religation of single-strand breaks when it binds to topoisomerase 1-DNA complex. Its cytotoxic action is due to the damage in double-strand DNA when replication enzymes act on the formed ternary complex.<br\/>"},{"id":"923686-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"923686-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 110 L\/m(2) to 234 L\/m(2)<\/li><li>Protein binding: 30% to 68%<\/li><\/ul>"},"2":{"id":"923686-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: Extensive, via various enzyme systems<\/li><li>Active metabolite: SN-38<\/li><\/ul>"},"3":{"id":"923686-s-8-26","title":"Excretion","mono":"<ul><li>Biliary plus renal: approximately 25% to 50% (in 48 hours)<\/li><li>Renal: 11% to 20%<\/li><li>Total body clearance: 13.3 to 13.9 L\/hr\/m(2)<\/li><\/ul>"},"4":{"id":"923686-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Irinotecan HCl: 6 to 12 hours<\/li><li>SN-38: 10 to 20 hours<\/li><\/ul>"}}},{"id":"923686-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>use proper procedures for the handling and disposal of chemotherapy<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>dilute in 250 mL to 500 mL or D5W (preferred) or NS to a final concentration of 0.12 to 2.8 mg\/mL<\/li><li>diluted solutions are stable at room temperature for 24 hours (use within 6 hours); D5W diluted solutions are stable for 48 hours in the refrigerator (use within 24 hours); do not refrigerate NS diluted solutions<\/li><li>administer as an IV infusion over 90 minutes; avoid extravasation<\/li><\/ul><\/li><\/ul>"},{"id":"923686-s-10","title":"Monitoring","mono":"<ul><li>evidence of tumor response is indicative of efficacy<\/li><li>WBC with differential, hemoglobin, and platelet count; prior to each dose<\/li><li>diarrhea, early and late onset, particularly in patients over 65 yr of age<\/li><li>infusion site; for signs of inflammation\/extravasation<\/li><\/ul>"},{"id":"923686-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Intravenous Solution: 20 MG\/ML<br\/><\/li><li><b>Amerinet Choice Irinotecan Hydrochloride<\/b><br\/>Intravenous Solution: 20 MG\/ML<br\/><\/li><li><b>Camptosar<\/b><br\/>Intravenous Solution: 20 MG\/ML<br\/><\/li><li><b>Novaplus Camptosar<\/b><br\/>Intravenous Solution: 20 MG\/ML<br\/><\/li><\/ul>"},{"id":"923686-s-12","title":"Toxicology","sub":[{"id":"923686-s-12-31","title":"Clinical Effects","mono":"<b>TOPOISOMERASE I INHIBITORS <\/b><br\/>OVERDOSE: Limited information available. Myelosuppression is the primary anticipated effect. ADVERSE EFFECTS: Myelosuppression as the dose-limiting toxicity, nausea, vomiting, diarrhea, abdominal pain, fever, dyspnea, increased coughing, headache, asthenia, paresthesia, alopecia and insomnia.<br\/>"},{"id":"923686-s-12-32","title":"Treatment","mono":"<b>TOPOISOMERASE I INHIBITORS<\/b><br\/><ul><li>Decontamination: DERMAL - Wash skin immediately with soap and water upon contact; flush mucous membranes copiously with water.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Myelosuppression: Severe neutropenia: filgrastim 5 mcg\/kg\/day subcutaneously. Transfusions as needed for thrombocytopenia, bleeding.<\/li><li>Fluid\/electrolyte balance regulation: Correct as indicated.<\/li><li>Pneumonitis: Monitor ABGs\/pulse oximetry, chest x-ray<\/li><li>Intrathecal injection: No clinical reports available, information derived from experience with other antineoplastics.  Immediately drain at least 20 mL CSF; drainage of up to 70 mL has been tolerated in adults.  Follow with CSF exchange (remove serial 20 mL aliquots CSF and replace with equivalent volumes of warmed, preservative free saline).  For large overdoses, consult a neurosurgeon for placement of a ventricular catheter and begin ventriculolumbar perfusion (infuse warmed preservative free normal saline through ventricular catheter, drain fluid from lumbar catheter; typical volumes 80 mL\/hr).  Albumin (5%) and FFP have also been used for perfusion, and may be useful because of the protein binding of these agents. Dexamethasone 4 mg intravenously every 6 hours to prevent arachnoiditis.<\/li><li>Monitoring of patient: Monitor CBC, fluid and electrolytes and respiratory function in patients with pneumonitis.<\/li><\/ul>"},{"id":"923686-s-12-33","title":"Range of Toxicity","mono":"<b>TOPOISOMERASE I INHIBITORS<\/b><br\/>TOXICITY: A toxic dose has not been established. Toxicity is anticipated to be an extension of adverse events reported with therapeutic use. THERAPEUTIC DOSE: TOPOTECAN: 2.3 mg\/m(2)\/day once daily for 5 days and repeated every 21 days. IRINOTECAN: 125 to 180 mg\/m(2) IV over 90 minutes; usually combined with other chemotherapeutic agents. The schedule of therapy varies depending on which drug combination is being used. <br\/>"}]},{"id":"923686-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause dizziness or visual disturbances, especially within 24 h after infusion. Patient should avoid driving or other activities requiring clear vision until drug effects are realized.<\/li><li>Advise patient to avoid vaccines during therapy due to drug-induced immunosuppression.<\/li><li>This drug may cause alopecia, nausea, vomiting, or interstitial lung disease.<\/li><li>Instruct patient to report diarrhea that occurs during or shortly after infusion. Inform patient that diarrhea may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, or abdominal cramping.<\/li><li>Patient should also report diarrhea that occurs more than 24 h after drug infusion. Instruct patient to take anti-diarrheal medicine only as prescribed by healthcare professional.<\/li><li>Patient should contact healthcare professional if diarrhea cannot be controlled within 24 h, nausea\/vomiting precludes patient from taking liquids, or patient has signs\/symptoms of dehydration or infection.<\/li><\/ul>"}]}